The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 13, 2010
Filed:
Dec. 05, 2007
Simeon Bowers, Oakland, CA (US);
Albert W. Garofalo, South San Francisco, CA (US);
Roy K. Hom, San Francisco, CA (US);
Andrei W. Konradi, Burlingame, CA (US);
Matthew N. Mattson, Santa Clara, CA (US);
Martin L. Neitzel, Pacifica, CA (US);
Christopher M. Semko, Fremont, CA (US);
Anh P. Truong, Burlingame, CA (US);
Jing Wu, Redwood City, CA (US);
Ying-zi Xu, Palo Alto, CA (US);
Simeon Bowers, Oakland, CA (US);
Albert W. Garofalo, South San Francisco, CA (US);
Roy K. Hom, San Francisco, CA (US);
Andrei W. Konradi, Burlingame, CA (US);
Matthew N. Mattson, Santa Clara, CA (US);
Martin L. Neitzel, Pacifica, CA (US);
Christopher M. Semko, Fremont, CA (US);
Anh P. Truong, Burlingame, CA (US);
Jing Wu, Redwood City, CA (US);
Ying-zi Xu, Palo Alto, CA (US);
Elan Pharmaceuticals, Inc., South San Francisco, CA (US);
Abstract
The invention provides N-cyclic sulfonamido compounds and salts of Formula I: wherein A is as described in the specification and Rand Rcombine to form a [3.3.1] or a [3.2.1] ring system, where the nitrogen is attached to the two bridgehead carbons, and the [3.3.1] or [3.2.1] ring systems are optionally fused with an heteroaryl or heterocycloalkyl ring. Compounds of Formula I are useful in treating or preventing cognitive disorders, such as Alzheimer's Disease. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I, methods of treating cognitive disorders, such as Alzheimer's disease, and the intermediates useful in preparing the compounds of Formula I.